HIV/AIDS: Epidemic update, new treatment strategies and impact on autoimmunity

Clinical and Experimental Rheumatology

Volumn 26, Issue 1 SUPPL. 48, 2008, Pages

  Croce, Francesco ^a   Piconi, Stefania ^c   Atzeni, Fabiola ^a   Sarzi Puttini, Piercarlo ^a   Galli, Massimo ^a   Clerici, Mario ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Clinical Immunology and Rheumatology Unit   (Italy)

Author keywords

Antiretroviral therapy; Autoimmunity; HIV; Lymphopenia

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; AUTOIMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG UTILIZATION; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDUSTRIALIZATION; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RHEUMATIC DISEASE; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; AUTOIMMUNE DISEASES; HUMANS;

EID: 42549083388     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 2007 AIDS epidemic update. December 2007. UNAIDS, Geneva
2. UNAIDS Reference Group on Estimates, Modelling and Projections. 2002. UNAIDS, Geneva
3. UNAIDS Reference Group on Estimates, Modelling and Projections. 2006. UNAIDS, Geneva
4. Aggiornamento dei casi di AIDS notificati in Italia e delle nuove diagnosi di infezione da HIV. Centro Operativo AIDS, Dicembre 2007
5. DE CLERCQ E: Anti-HIV drugs. Verh K Acad Geneeskd Belg 2007; 69: 81-104.
6. SIMON V, HO DD, ABDOOL KARIM Q: HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489-504.
7. KILLINGLEY B, POZNIAK A: The first once-daily single tablet regimen for the treatment of HIV-infected patients. VDrugs Today (Barc) 2007; 43: 427-42.
8. UNAIDS, 2006 report on the global AIDS epidemic: A UNAIDS 10th anniversary special edition http://www.unaids.org/en/HIV_data/ 2006GlobalReport/default.asp (accessed July 20, 2006).
9. CALMY A, KLEMENT E, TECK R, BERMAN D, PECOUL B, FERRADINI L: Simplifying and adapting antiretroviral treatment in resource-poor settings: A necessary step to scaling-up. AIDS 2004; 18: 2353-60.
10. KOBER K, VAN DAMME W: Scaling up access to antiretroviral treatment in southern Africa: Who will do the job? Lancet 2004; 364: 103-7.
11. LIBAMBA E, MAKOMBE S, HARRIES AD et al.: Scaling up antiretroviral therapy in Africa: Learning from tuberculosis control programmes - the case of Malawi. Int J Tuberc Lung Dis 2005; 9: 1062-71.
12. GUPTA R, IRWIN A, RAVIGLIONE MC, KIM JY: Scaling-up treatment for HIV/ AIDS: Lessons learned from multidrug-resistant tuberculosis. Lancet 2004; 363: 320-4.
13. RATHBUN RC, LOCKHART SM, STEPHENS JR: Current HIV treatment guidelines - an overview. Curr Pharm Des 2006; 12: 1045-63.
14. DYBUL M, FAUCI AS, BARTLETT JG, KAPLAN JE, PAU AK: Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137: 381-433.
15. CAROSI G, TORTI C, ANDREONI M et al.: Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). J Antimicrob Chemother 2006; 57:1055-64.
16. YENI PG, HAMMER SM, CARPENTER CC et al.: Antiretrovirai treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288: 222-35.
17. EACS - Guidelines for the clinical management and treatment of HIV-infected adults in Europe/Version 2. Dec 2007 (http://www.eacs.eu/guide/1).
18. DHHS - Guidelines for the use of antiretroviral agents in HIv-1 infected adults and Adolescents. December, 1, 2007 (http://www.aidsinfo.nih.gov/guidelines).
19. HAMMER SM, SAAG MS, SCHECHTER M et al.: International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.
20. GATELL JM: Early antiretRoviral therapy: rationale, protease inhibitor-sparing regimens and once daily dosing. Antivir Ther 1998; 3: 49-53.
21. MEHANDRU S, TENNER-RACZ K, RACZ P AND MARKOWITZ M: The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. J Allergy Clin Immunol 2005; 116: 419-22.
22. YLISASTIGUI, NM ARCHIN, G LEHRMAN, RJ BOSCH, DM MARGOLIS: Coaxing HIV-1 from resting CD4 T cells: Histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18: 1101-8.
23. LEHRMAN G, HOGUE IB, PALMER S et al.: Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 2005; 366: 549-55.
24. SG DEEKS: Treatment of antiretroviral-drug-resistant HIV infection. Lancet 2003; 362: 2002-11.
25. KANTOR R, KATZENSTEIN DA, EFRON B et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005; 2: 112.
26. PARKIN NT, SCHAPIRO JM: Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9: 3-12.
27. STEAIN MC, WANG B, DWYER DE, SAKSENA NK: HIV-1 co-infection, superinfection and recombination. Sex Health 2004; 1: 239-50.
28. NELSON M, FAKENHEUER G, KONOURINA I et al.: Efficacy and safety of maraviroc plus optimised background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 141, Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 104aLB
29. LALEZARI J, GOODRICH J, DEJESUS E et al.: Efficacy and safety of maraviroc plus optimised background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/ 3 study in the US and Canada. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 104aLB.
30. COOPER D, GATELL J, ROCKSTROH J et al.: Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 105aLB.
31. STEIGBIGEL R, KUMAR P, ERON J et al.: Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007; Los Angeles, CA. Abstract 105bLB.
32. ANDRIES K, AZIJN H, THIELEMANS T et al.: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
33. LAZZARIN A, CAMPBELL T, CLOTET B et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
34. MADRUGA JV, CAHN P, GRINSZTEJN B et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
35. SCHÜMANN D, FÄTKENHEUER G, REYNES J et al.: Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21: 1293-9.
36. GULICK RM, SU Z, FLEXNER C et al.: Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatmentexperienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196: 304-12.
37. SMITH P, FORREST A, BEATTY G et al.: Pharmacokinetics/ Pharmacodynamics of PA-457 in a 10-day Multiple Dose Monotherapy Trial in HIV-infected Patients. 13th, Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract 52.
38. ESSER S, HELBIG D, HILLEN U, DISSEMOND, J, GRABBE S: Side effects of HIV therapy. J Dtsch Dermatol Ges 2007; 5: 745-54.
39. PALELLA FJ, BAKER RK, MOORMAN AC et al.: HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
40. WILLIAM FM, COHEN PR, JUMSHYD J, REVEILLE JD: Prevalence of the diffuse infiltrative lymphocytosis syndrome among human immunodeficiency virus type I-positive patients. Arthritis Rheum 1998; 41: 863-8.
41. FRENCH MA, PRICE P, STONE SF: Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-27.
42. GLEESON PA, TOH BH, VAN DRIEL IR: Organ-specific autoimmunity induced by lymphopenia Immunol Rev 1996; 149: 97-125.
43. KING C, ILIC A, KOELSCH K, SARVETNICK N: Homeostasis expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117: 265-77.
44. + T cells induce or protect from chronic intestinal inflammation in B-17 scid mice. Int Immunol 1993; 5: 1461-71.
45. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
46. + regulatory T cells is necessary, but non sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002; 168: 5979-83.
47. + regulatory T cells. Nat Med 2005; 11: 1238-43.
48. DE KLEER I: Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring network. Blood 2005; 12: 1165-72.
49. DESIMONE JA, BABINCHAK TJ: Inflammatory reaction in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern. Med 2000; 133: 447-54.
50. STOLL M, SCHMIDT RE: Adverse events of desiderable gain in immunocompetence: The immune restoration inflammatory syndrome. Autoimmun Rev 2004; 3: 243-49.